# A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

> **NCT01514461** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome (FCS)

## Interventions

- **DRUG:** LCQ908
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01514461
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514461, "A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01514461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*